Site Registration
Registration benefits include:
- Access to CME/CE programs
- Free subscription to Current Medical Evidence
- Reminders of new CME/CE activities
About This Section
Access a regularly updated listing of late-stage clinical trials of high relevance to clinicians who provide care to patients who have or are at risk for osteoporosis. Featured in the most recent update are studies on postmenopausal osteoporosis, secondary osteoporosis, osteoporosis in men, hip and vertebral fracture prevention, and therapeutic agents such as bisphosphonates, calcitonin, denosumab, estrogen, odanacatib, parathyroid hormone analogs, estrogen receptor agonists/antagonists, and other drugs in development.
Other Agents
Densosumab
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis - The ADAMO Trial
Conditions: Low Bone Mass; Low Bone Mineral Density; Males With Osteoporosis; Osteopenia; Osteoporosis
Interventions: Drug: 60 mg denosumab; Other: Placebo
Sponsor: Amgen
Recruiting - verified August 2010
A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
Condition: Postmenopausal Osteoporosis
Interventions: Drug: Ibandronate; Drug: Denosumab
Sponsor: Amgen
Recruiting - verified August 2010
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsor: Amgen
Recruiting - verified September 2010
Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy
Condition: Osteoporosis
Interventions: Drug: Actonel®; Drug: amg 162
Sponsor: Amgen
Recruiting - verified September 2010
A HR-pQCT Study in Postmenopausal Women Previously Treated With Denosumab
Conditions: Low Bone Mass; Low Bone Mineral Density; Osteoporosis; Postmenopausal Osteoporosis
Intervention: Procedure: HR-pQCT, DXA and BTM measurements
Sponsor: Amgen
Completed - verified August 2010
Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
Condition: Osteoporosis
Interventions: Drug: Denosumab; Drug: Placebo; Drug: Alendronate sodium hydrate
Sponsor: Daiichi Sankyo Co., Ltd.
Active, not recruiting - verified June 2009
Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis
Conditions: Osteopenia; Osteoporosis
Intervention: Drug: denosumab
Sponsor: Amgen
Active, not recruiting - verified June 2010
Denosumab Adherence Preference Satisfaction Study
Condition: Osteoporosis
Interventions: Drug: denosumab; Drug: alendronate
Sponsor: Amgen
Active, not recruiting - verified June 2010
A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density
Conditions: Low Bone Mineral Density; Osteopenia; Osteoporosis
Interventions: Biological: denosumab; Biological: denosumab
Sponsor: Amgen
Active, not recruiting - verified December 2009
Study of Transitioning From Alendronate to Denosumab
Condition: Postmenopausal Osteoporosis
Interventions: Drug: alendronate; Drug: Denosumab (AMG 162)
Sponsor: Amgen
Completed - verified July 2010
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
Condition: Low Bone Mineral Density
Intervention: Drug: AMG 162
Sponsor: Amgen
Active, not recruiting - verified April 2010
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
Conditions: Osteoporosis; Osteopenia
Interventions: Drug: Alendronate; Drug: Denosumab
Sponsor: Amgen
Completed - verified June 2010
Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
Condition: Postmenopausal Osteoporosis
Interventions: Drug: AMG 162; Drug: Placebo
Sponsor: Amgen
Completed - verified March 2010
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis
Condition: Osteoporosis
Interventions: Drug: placebo; Drug: denosumab
Sponsor: Amgen
Completed - verified June 2010
Odanacatib
A Study to Assess Safety and Efficacy of Odanacatib (MK0822) in Men With Osteoporosis (0822-053)
Condition: Osteoporosis
Interventions: Drug: odanacatib; Drug: Comparator: Placebo; Dietary Supplement: Comparator: Vitamin D3; Dietary Supplement: Comparator: Calcium carbonate
Sponsor: Merck
Recruiting - verified August 2010
BMD Efficacy and Safety of Odanacatib in Postmenopausal Women
Condition: Osteoporosis
Interventions: Drug: Comparator: Odanacatib; Drug: Comparator: Placebo
Sponsor: Merck
Active, not recruiting - verified April 2010
A Study of MK0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk
Condition: Postmenopausal Osteoporosis
Interventions: Drug: Comparator: odanacatib; Drug: Comparator: Placebo; Dietary Supplement: Comparator: Vitamin D3; Dietary Supplement: Comparator: calcium carbonate
Sponsor: Merck
Active, not recruiting - verified May 2010
